8-K: Passage Bio Reports Positive Clinical Trial Progress and Financial Update for Q3 2024

Passage Bio announced encouraging clinical trial progress for its PBFT02 gene therapy, along with a financial update showing a cash runway into Q2 2026.

Summary

• Passage Bio reported its financial results for the third quarter of 2024, ending September 30, 2024.
• The company has enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing progressing as planned.
• They expect to share 12-month Cohort 1 and interim Cohort 2 data in the first half of 2025.
• Interim data from Cohort 1 showed PBFT02 was generally well-tolerated and elevated CSF progranulin levels for up to 12 months post-treatment.
• Preclinical data supports PBFT02 as a potential best-in-class progranulin-raising therapy.
• The company's cash, cash equivalents, and marketable securities totaled $84.8 million as of September 30, 2024.
• Passage Bio anticipates its current cash, along with remaining payments from out-licensing agreements, will fund operations through the end of Q2 2026.
• Research and development expenses were $8.7 million for the quarter, compared to $15.1 million in the same quarter of 2023.
• General and administrative expenses were $7.3 million for the quarter, down from $8.2 million in the same quarter of 2023.
• The net loss for the quarter was $19.3 million, or $0.31 per share, compared to a net loss of $27.1 million, or $0.49 per share, in the same quarter of 2023.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the encouraging clinical trial progress, strong preclinical data, and extended cash runway. The company is making good progress in its core programs and has a clear path forward. However, the net loss and decrease in cash reserves temper the overall sentiment slightly.

Positives

• The company is making good progress in its clinical trials, with patient enrollment and dosing proceeding as planned.
• The interim data from the upliFT-D trial shows that PBFT02 is well-tolerated and effectively increases progranulin levels.
• The company has a strong cash position that is expected to fund operations through Q2 2026.
• Preclinical data supports the potential of PBFT02 as a best-in-class therapy.
• The company is actively presenting its data at key scientific conferences.
• The appointment of Tom Kassberg to the board brings valuable experience in corporate development and strategic planning.

Negatives

• The company experienced a net loss of $19.3 million for the quarter.
• Cash reserves have decreased from $132.8 million in September 2023 to $84.8 million in September 2024.
• Research and development expenses, while lower than the previous year, still represent a significant cost.

Risks

• The company's ability to develop and obtain regulatory approval for its product candidates is subject to risk.
• Clinical trial results may not be replicated in subsequent trials, and success in early-stage trials may not predict results in later-stage trials.
• The company is dependent on collaborators and third parties for development and manufacturing.
• There are risks associated with potential delays, work stoppages, or supply chain disruptions.
• The company's intellectual property may not be adequately protected or enforced.

Future Outlook

The company anticipates reporting 12-month Cohort 1 and interim Cohort 2 data in the first half of 2025, seeking regulatory feedback on pivotal trial design in the second half of 2025, and initiating dosing of FTD-C9orf72 patients in the first half of 2025. They also expect to obtain regulatory feedback on the pathway to treating ALS patients in the second half of 2024. The company expects its current cash to fund operations through the end of Q2 2026.

Management Comments

• Will Chou, M.D., president and chief executive officer of Passage Bio, stated that the company has made important strides in advancing their PBFT02 gene therapy program.
• He also noted that the execution of the ongoing upliFT-D trial for FTD-GRN remains their core priority.
• He highlighted the potential of PBFT02 to be a market-leading progranulin-raising therapy.

Industry Context

This announcement is relevant to the gene therapy and neurodegenerative disease treatment sectors. The focus on FTD-GRN and other related conditions aligns with the growing interest in addressing rare and challenging neurological disorders. The company's progress in clinical trials and preclinical research positions them as a potential player in the market for gene therapies targeting these conditions.

Comparison to Industry Standards

• Passage Bio's approach of using an AAV1 vector for gene delivery is notable, as it has shown superior progranulin levels in preclinical studies compared to AAV5 and AAVhu68, which are commonly used in gene therapy.
• The company's focus on intra-cisterna magna (ICM) administration is a less invasive method compared to other delivery methods, potentially reducing risks and improving patient outcomes.
• The reported increase in CSF progranulin levels and the favorable safety profile of PBFT02 are promising and align with the goals of gene therapy for neurodegenerative diseases.
• Companies like BioMarin and Sarepta Therapeutics have also made significant strides in gene therapy, but Passage Bio's focus on FTD-GRN and other related conditions differentiates them.
• The cash runway to Q2 2026 is a positive sign, as many biotech companies face funding challenges, and this provides Passage Bio with a longer period to execute their clinical programs.

Management Changes

Stakeholder Impact

• Shareholders will be encouraged by the positive clinical trial data and extended cash runway.
• Employees will be motivated by the company's progress and clear path forward.
• Patients and families affected by neurodegenerative diseases will be hopeful about the potential of PBFT02.
• Collaborators and partners will be reassured by the company's strong financial position and execution.

Next Steps

• The company will report 12-month Cohort 1 and interim Cohort 2 data in the first half of 2025.
• They will seek regulatory feedback on pivotal trial design in the second half of 2025.
• The company plans to initiate dosing of FTD-C9orf72 patients in the first half of 2025.
• They will obtain regulatory feedback on the pathway to treating ALS patients in the second half of 2024.

Key Dates

Keywords

gene therapy, neurodegenerative diseases, progranulin, FTD-GRN, PBFT02, clinical trial, AAV1 vector, lysosomal dysfunction, biomarkers, cash runway